✦ LIBER ✦

Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors

✍ Scribed by Johanna C. Bendell; Joseph P. Eder; Jeffrey W. Clark; Panagiotis Fidias; Thomas J. Lynch; Michael V. Seiden; David P. Ryan

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 84 KB
Volume: 103
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose escalation study of tezacitabine in

Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer

✍ Keith T. Flaherty; James P. Stevenson; Maryann Gallagher; Bruce Giantonio; Kenne 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract ## BACKGROUND The authors performed a dose escalation study of cisplatin and the novel deoxycytidine analog, tezacitabine, to determine the maximum tolerated dose of the combination. ## METHODS Twenty‐three patients with advanced cancer and good performance status were accrued to 3 d

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

Phase I study to evaluate multiple regim

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors : A potential broadly active regimen for advanced solid tumor malignancies

✍ Sridhar Mani; Nicholas J. Vogelzang; Donna Bertucci; Walter M. Stadler; Richard 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

Temozolomide in combination with interfe

Temozolomide in combination with interferon α-2b in patients with metastatic melanoma : A Phase I dose-escalation study

✍ Sanjiv S. Agarwala; John M. Kirkwood 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

## Abstract ## BACKGROUND Metastatic melanoma (MM) is associated with a high risk of central nervous system (CNS) metastases, and current chemotherapy does not adequately treat or protect patients with MM against CNS metastases. Therefore, the authors initiated a Phase I study to determine the pha

A Phase I study of bortezomib plus irino

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors

✍ David P. Ryan; Bert H. O'Neil; Jeffrey G. Supko; Carlo M. Rocha Lima; E. Claire 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB 👁 2 views

A phase I trial of cisplatin in hyperton

A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies

✍ Leonard Saltz; David Kelsen 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 427 KB 👁 2 views